Topical Corticosteroid Switches Must Overcome Side Effect Concerns – Panel
This article was originally published in The Tan Sheet
Executive Summary
Topical corticosteroid manufacturers will have to overcome a high burden of proof to convince FDA that side effects related to cortisol suppression from using the drugs are outweighed by their benefits when seeking an Rx-to-OTC switch
You may also be interested in...
Steroid Nasal Sprays Not Suitable For Rx-to-OTC Switch – Task Force
The potential for consumers to overdose on intranasal corticosteroids without physician guidance makes the drug category inappropriate for Rx-to-OTC switch, a recent task force report finds
Steroid Nasal Sprays Not Suitable For Rx-to-OTC Switch – Task Force
The potential for consumers to overdose on intranasal corticosteroids without physician guidance makes the drug category inappropriate for Rx-to-OTC switch, a recent task force report finds
Steroid Nasal Sprays Not Suitable For Rx-to-OTC Switch – Task Force
The potential for consumers to overdose on intranasal corticosteroids without physician guidance makes the drug category inappropriate for Rx-to-OTC switch, a recent task force report finds